Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M7,740Revenue (TTM) $M804Net Margin (%)-24.3Altman Z-Score8.5
Enterprise Value $M7,547EPS (TTM) $-1.3Operating Margin %-24.9Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.8Pre-tax Margin (%)-25.9Higher ROA y-yY
Price/Book6.410-y EBITDA Growth Rate %--Quick Ratio3.2Cash flow > EarningsY
Price/Sales9.65-y EBITDA Growth Rate %--Current Ratio3.5Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-11.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-16.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M154ROIC % (ttm)-19.2Gross Margin Increase y-yY

Gurus Latest Trades with ALKS

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

ALKS is held by these investors:

ALKS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKS 2017-09-11Sell13,566$51.29-1.79view
MITCHELL PAUL JDirector 2017-09-01Sell1,500$50.77-0.79view
MITCHELL PAUL JDirector 2017-08-01Sell1,500$54.91-8.27view
MITCHELL PAUL JDirector 2017-07-03Sell1,500$58.11-13.32view
Stejbach MarkSVP/Chief Comm Off, Alks Inc 2017-06-08Sell10,000$60.34-16.52view
Cooke ShanePresident, Alkermes plc 2017-06-08Sell10,000$60.33-16.51view
MITCHELL PAUL JDirector 2017-06-01Sell1,500$57.49-12.38view
POPS RICHARD FDirector and CEO, Alkermes plc 2017-05-24Sell25,000$57.42-12.28view
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc. 2017-05-18Sell10,000$57.23-11.99view
POPS RICHARD FDirector and CEO, Alkermes plc 2017-05-17Sell50,000$58.19-13.44view

Quarterly/Annual Reports about ALKS:

News about ALKS:

Articles On GuruFocus.com
What Markets Are Really Looking for in Alkermes' Schizophrenia Drug Jul 05 2017 
7 Outperforming Stocks With Rising Prices Jun 27 2017 
Stocks That Are Beating the Market Apr 12 2017 
Drug Addiction Treatment Should Start in Emergency Room Apr 04 2017 
Who Is Winning the Fight Against Opioid Abuse? Feb 27 2017 
Naltrexone Showing More Potential in Drug Addiction Treatment Market Feb 05 2017 
BioCorRx Receives New Funding for Opioid Drug Jan 22 2017 
US Prisons Experiment With Addiction Treatment for Inmates Nov 29 2016 
AvalonBay Communities, Equinix, Jarden, Alkermes Approach 52-Week Highs Jan 04 2016 
Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter Apr 30 2012 

More From Other Websites
See what the IHS Markit Score report has to say about Alkermes PLC. Sep 22 2017
Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia Sep 19 2017
Patients Switched to Alkermes’ ARISTADA® Showed Significant Improvement in Schizophrenia Symptoms... Sep 18 2017
[$$] Merck Tops JNJ, Allergan Sep 08 2017
Three Pharma Stocks To Buy As 2017 Ends With A Whimper Sep 08 2017
Alkermes Announces 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health... Sep 06 2017
Alkermes to Present at the Morgan Stanley 15th Annual Global Healthcare Conference Sep 05 2017
Alkermes to Present Clinical and Real-World Data at Upcoming 30th Annual Psych Congress Sep 05 2017
Biotech Stock Roundup: EU Label Expansion for Alexion, BIIB Facing Drug Price Probe Aug 23 2017
Alkermes Initiates Rolling Submission of Depression Drug Aug 22 2017
Alkermes Initiates Rolling Submission of ALKS 5461 New Drug Application for Major Depressive... Aug 21 2017
ETFs with exposure to Alkermes Plc : August 14, 2017 Aug 14 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat